BACKGROUND: We assessed for CD30 expression in patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome (MDS) to examine the possibility that anti-CD30 could be targeted therapy in these patients. METHODS: Multicolor flow cytometry immunophenotypic analysis was performed on bone marrow aspirates of 135 patients with AML or MDS and peripheral blood samples in a subset of 33 patients. Immunohistochemistry was performed on bone marrow aspirate clot specimens of 84 patients. RESULTS: The median patient age was 63 years (range, 13-92 years); 102 (75%) patients had refractory or recurrent disease, and 68 (50%) had high-risk cytogenetics. Overall, the median percentage of blasts positive for CD30 was 14% (range, 0%-91%). By using an arbitrary 20% cutoff, 49 (36%) patients were considered to have CD30 expression. Monocytic cells, either mature or immature, were consistently negative for CD30. Therefore, CD30 expression was less in AML with monocytic differentiation (P = .006). The patients with persistent disease who had been actively treated had a higher level of CD30 expression than the patients who were untreated (P = .031). In paired samples, CD30 expression was consistently higher in bone marrow blasts than in peripheral blood blasts (P = .002). Immunohistochemistry demonstrated CD30 expression by myeloblasts in a subset of patients, but reactivity was generally weaker and focally compared. CONCLUSIONS: CD30 is expressed by myeloblasts in a substantial subset of patients with AML or MDS. Because the study group was composed mostly of patients with high-risk AML or MDS in whom very few treatment options are available, these data raise the possibility that anti-CD30-targeted therapy could be a potential option for this patient group.
BACKGROUND: We assessed for CD30 expression in patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome (MDS) to examine the possibility that anti-CD30 could be targeted therapy in these patients. METHODS: Multicolor flow cytometry immunophenotypic analysis was performed on bone marrow aspirates of 135 patients with AML or MDS and peripheral blood samples in a subset of 33 patients. Immunohistochemistry was performed on bone marrow aspirate clot specimens of 84 patients. RESULTS: The median patient age was 63 years (range, 13-92 years); 102 (75%) patients had refractory or recurrent disease, and 68 (50%) had high-risk cytogenetics. Overall, the median percentage of blasts positive for CD30 was 14% (range, 0%-91%). By using an arbitrary 20% cutoff, 49 (36%) patients were considered to have CD30 expression. Monocytic cells, either mature or immature, were consistently negative for CD30. Therefore, CD30 expression was less in AML with monocytic differentiation (P = .006). The patients with persistent disease who had been actively treated had a higher level of CD30 expression than the patients who were untreated (P = .031). In paired samples, CD30 expression was consistently higher in bone marrow blasts than in peripheral blood blasts (P = .002). Immunohistochemistry demonstrated CD30 expression by myeloblasts in a subset of patients, but reactivity was generally weaker and focally compared. CONCLUSIONS:CD30 is expressed by myeloblasts in a substantial subset of patients with AML or MDS. Because the study group was composed mostly of patients with high-risk AML or MDS in whom very few treatment options are available, these data raise the possibility that anti-CD30-targeted therapy could be a potential option for this patient group.
Authors: S A Pileri; S Ascani; M C Cox; C Campidelli; F Bacci; M Piccioli; P P Piccaluga; C Agostinelli; S Asioli; D Novero; M Bisceglia; M Ponzoni; A Gentile; P Rinaldi; V Franco; D Vincelli; A Pileri; R Gasbarra; B Falini; P L Zinzani; M Baccarani Journal: Leukemia Date: 2006-12-14 Impact factor: 11.528
Authors: V Gattei; M Degan; A Gloghini; A De Iuliis; S Improta; F M Rossi; D Aldinucci; V Perin; D Serraino; R Babare; V Zagonel; H J Gruss; A Carbone; A Pinto Journal: Blood Date: 1997-03-15 Impact factor: 22.113
Authors: George Z Rassidakis; Athanasios Thomaides; Coralyn Atwell; Richard Ford; Dan Jones; Francois-Xavier Claret; L Jeffrey Medeiros Journal: Mod Pathol Date: 2005-10 Impact factor: 7.842
Authors: P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett Journal: Blood Date: 1997-03-15 Impact factor: 22.113
Authors: Zhuang Zuo; Su S Chen; Pranil K Chandra; John M Galbincea; Matthew Soape; Steven Doan; Bedia A Barkoh; Hartmut Koeppen; L Jeffrey Medeiros; Rajyalakshmi Luthra Journal: Mod Pathol Date: 2009-05-08 Impact factor: 7.842
Authors: Wenli Zheng; L Jeffrey Medeiros; Ken H Young; Maitrayee Goswami; Linda Powers; Hagop H Kantarjian; Deborah A Thomas; Jorge E Cortes; Sa A Wang Journal: Leuk Lymphoma Date: 2013-08-13
Authors: Michael J Peluso; Cassandra Thanh; Cecilia A Prator; Louise E Hogan; Victor M Arechiga; Sophie Stephenson; Philip J Norris; Clara Di Germanio; Dietmar Fuchs; Henrik Zetterberg; Steven G Deeks; Magnus Gisslén; Richard W Price; Timothy J Henrich Journal: J Virus Erad Date: 2020-02-20